HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
-
REGULATORY Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
-
REGULATORY Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
-
BUSINESS Arcalis Sees Opportunities in mRNA Drugs, Eyes Tens of Billions of Yen in CDMO Sales
July 19, 2021
-
REGULATORY New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
-
REGULATORY Japan to Lower Moderna Vaccine’s Minimum Age to 12
July 16, 2021
-
BUSINESS Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
-
BUSINESS Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too
July 14, 2021
-
REGULATORY Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
-
COMMENTARY Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
-
ACADEMIA Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
-
BUSINESS Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
July 9, 2021
-
BUSINESS FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s
July 9, 2021
-
BUSINESS Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
-
BUSINESS Bristol Myers Kicks Off COVID-19 Inoculation Program, Eliminates Cost Burden on Employees
July 8, 2021
-
BUSINESS 26 Japan Drug Makers’ Annual Pay Averages 8.21 Million Yen, 5 Firms Top 10 Million Yen Mark
July 7, 2021
-
BUSINESS Astellas Revamping Sales Organization as Product Mix Shifts towards Specialty Area: CEO
July 6, 2021
-
BUSINESS Sagent Jettisons Camostat Mesilate for COVID-19 after PII Miss: Nichi-Iko
July 6, 2021
-
BUSINESS All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
-
BUSINESS Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
